Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: A new paradigm for understanding the therapeutic effect of combined treatment

European Journal of Cancer

Volumn 46, Issue 16, 2010, Pages 3022-3036

  Ortholan, Cécile ^a   Durivault, Jérôme ^a   Hannoun Levi, Jean Michel ^b   Guyot, Mélanie ^a   Bourcier, Christine ^a   Ambrosetti, Damien ^a   Safe, Stephen ^c   Pags, Gilles ^a  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

^b CENTRE ANTOINE LACASSAGNE   (France)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Angiogenesis; Bevacizumab; Breast and prostate tumours; Docetaxel

Indexed keywords

BEVACIZUMAB; DOCETAXEL; TRANSCRIPTION FACTOR SP1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CELL SURVIVAL; CONTROLLED STUDY; CYTOPLASM; DRUG EFFICACY; DRUG POTENTIATION; GENE ACTIVATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN LOCALIZATION; TRANSCRIPTION INITIATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL DIVISION; CELL SURVIVAL; CYTOPLASM; FEMALE; HUMANS; MALE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; SP1 TRANSCRIPTION FACTOR; TAXOIDS; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 78049318854     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.07.021     Document Type: Article

References (63)

1. J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease Nat Med 1 1 1995 27 31
2. N. Ferrara, and K. Alitalo Clinical applications of angiogenic growth factors and their inhibitors Nat Med 5 12 1999 1359 1364
3. R.A. Burger Experience with bevacizumab in the management of epithelial ovarian cancer J Clin Oncol 25 20 2007 2902 2908
4. S.A. Cannistra, U.A. Matulonis, and R.T. Penson Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J Clin Oncol 25 33 2007 5180 5186
5. B.J. Giantonio, P.J. Catalano, and N.J. Meropol Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 12 2007 1539 1544
6. M.A. Cobleigh, V.K. Langmuir, and G.W. Sledge A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer Semin Oncol 30 5 Suppl. 16 2003 117 124
7. J.C. Yang, L. Haworth, and R.M. Sherry A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 5 2003 427 434
8. A. Sandler, R. Gray, and M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 24 2006 2542 2550
9. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 23 2004 2335 2342
10. J.A. Foekens, H.A. Peters, and N. Grebenchtchikov High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer Cancer Res 61 14 2001 5407 5414
11. R.A. Bok, S. Halabi, and D.T. Fei Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study Cancer Res 61 6 2001 2533 2536 (Pubitemid 32685834)
12. D.J. George, S. Halabi, and T.F. Shepard Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480 Clin Cancer Res 7 7 2001 1932 1936 (Pubitemid 32994827)
13. B. Ramaswamy, A.D. Elias, and N.T. Kelbick Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients Clin Cancer Res 12 10 2006 3124 3129 (Pubitemid 43837360)
14. K. Miller, M. Wang, and J. Gralow Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 26 2007 2666 2676
15. D. Miles, A. Chan, and G. Romieu Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO J Clin Oncol 26 May 20 2008 Abstract LBA 1011
16. D. Reese, P. Fratesi, and M. Corry A phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer The Prostate J 3 2 2001 65 70
17. Picus J, Halabi S, Rini B, et al. The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): initial results of CALGB 90006. Proc Am Soc Clin Oncol 22;2003 [2003:Abstract No: 1578].
18. Di Lorenzo G, Figg WD, Fossa SD, et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol 2008.
19. D.P. Petrylak, C.M. Tangen, and M.H. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 15 2004 1513 1520
20. R.K. Jain Antiangiogenic therapy for cancer: current and emerging concepts Oncology (Williston Park) 19 4 Suppl 3 2005 7 16
21. A.D. Yang, T.W. Bauer, and E.R. Camp Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy Cancer 103 8 2005 1561 1570
22. D.S. Grant, T.L. Williams, M. Zahaczewsky, and A.P. Dicker Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere) Int J Cancer 104 1 2003 121 129
23. C. Moser, S.A. Lang, and O. Stoeltzing The direct effects of anti-vascular endothelial growth factor therapy on tumor cells Clin Colorectal Cancer 6 8 2007 564 571
24. L. Legros, C. Bourcier, and A. Jacquel Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia Blood 104 2 2004 495 501
25. K.J. Higgins, M. Abdelrahim, S. Liu, K. Yoon, and S. Safe Regulation of vascular endothelial growth factor receptor-2 expression in pancreatic cancer cells by Sp proteins Biochem Biophys Res Commun 345 1 2006 292 301 (Pubitemid 44269283)
26. J. Milanini, F. Vinals, J. Pouysségur, and G. Pags p42/p44 MAP Kinase module plays a key role in the transcriptional regulation of vascular endothelial growth factor gene in fibroblasts J Biol Chem 273 1998 18165 18172
27. A. Gampel, L. Moss, and M.C. Jones VEGF regulates the mobilization of VEGFR2/KDR from an intracellular endothelial storage compartment Blood 108 8 2006 2624 2631
28. K. Essafi-Benkhadir, C. Onesto, E. Stebe, C. Moroni, and G. Pages Tristetraprolin inhibits Ras-dependent tumor vascularization by inducing vascular endothelial growth factor mRNA degradation Mol Biol Cell 18 11 2007 4648 4658
29. Y. Wang, D. Fei, M. Vanderlaan, and A. Song Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro Angiogenesis 7 4 2004 335 345
30. J.T. Lee Jr., L.S. Steelman, and J.A. McCubrey Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells Cancer Res 64 22 2004 8397 8404
31. A. Hirata, S. Ogawa, and T. Kometani ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase Cancer Res 62 9 2002 2554 2560
32. C.K. Goldman, J. Kim, and W.L. Wong Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology Mol Biol Cell 4 1 1993 121 133
33. N. Ferrara, K. Carver-Moore, and H. Chen Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene Nature 380 6573 1996 439 442
34. Y. Dor, V. Djonov, and R. Abramovitch Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy Embo J 21 8 2002 1939 1947
35. K. Alitalo, and P. Carmeliet Molecular mechanisms of lymphangiogenesis in health and disease Cancer Cell 1 3 2002 219 227
36. M. Shibuya Vascular endothelial growth factor (VEGF)-Receptor2: its biological functions, major signaling pathway, and specific ligand VEGF-E Endothelium 13 2 2006 63 69
37. S.E. Duff, M. Jeziorska, and D.D. Rosa Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy Eur J Cancer 42 1 2006 112 117
38. G. Giannelli, A. Azzariti, and C. Sgarra ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells Biochem Pharmacol 71 4 2006 479 485
39. A.D. Yang, E.R. Camp, and F. Fan Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells Cancer Res 66 1 2006 46 51 (Pubitemid 43166007)
40. A. Hiramatsu, H. Miwa, and M. Shikami Disease-specific expression of VEGF and its receptors in AML cells: possible autocrine pathway of VEGF/type1 receptor of VEGF in t(15;17) AML and VEGF/type2 receptor of VEGF in t(8;21) AML Leuk Lymphoma 47 1 2006 89 95
41. T. Seto, M. Higashiyama, and H. Funai Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer Lung Cancer 53 1 2006 91 96
42. P.M. Lacal, F. Ruffini, E. Pagani, and S. D'Atri An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells Int J Oncol 27 6 2005 1625 1632
43. L. Claesson-Welsh Signal transduction by vascular endothelial growth factor receptors Biochem Soc Trans 31 Pt. 1 2003 20 24
44. L. Ryden, B. Linderholm, and N.H. Nielsen Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer Breast Cancer Res Treat 82 3 2003 147 154
45. B. Gril, D. Palmieri, and J.L. Bronder Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain J Natl Cancer Inst 100 15 2008 1092 1103
46. F.M. Uckun, R.K. Narla, and X. Jun Cytotoxic activity of epidermal growth factor-genistein against breast cancer cells Clin Cancer Res 4 4 1998 901 912
47. C. Timke, H. Zieher, and A. Roth Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy Clin Cancer Res 14 7 2008 2210 2219
48. D. Kong, S. Banerjee, and W. Huang Mammalian target of rapamycin repression by 3,3'-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells Cancer Res 68 6 2008 1927 1934
49. G. Pags, E. Berra, J. Milanini, A.P. Levy, and J. Pouysségur Stress-activated protein kinases (JNK and p38/HOG) are essential for vascular endothelial growth factor mRNA stability J Biol Chem 275 34 2000 26484 26491
50. D.O. Bates, T.G. Cui, and J.M. Doughty VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma Cancer Res 62 14 2002 4123 4131
51. I.A. Avramis, R. Kwock, and V.I. Avramis Taxotere and vincristine inhibit the secretion of the angiogenesis inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukemia T-cell lines Anticancer Res 21 4A 2001 2281 2286
52. K. Keyes, K. Cox, and P. Treadway An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy Cancer Res 62 19 2002 5597 5602
53. P. Lissoni, E. Fugamalli, and F. Malugani Chemotherapy and angiogenesis in advanced cancer: vascular endothelial growth factor (VEGF) decline as predictor of disease control during taxol therapy in metastatic breast cancer Int J Biol Markers 15 4 2000 308 311
54. M. Sonee, E. Barron, F.A. Yarber, and S.F. Hamm-Alvarez Taxol inhibits endosomal-lysosomal membrane trafficking at two distinct steps in CV-1 cells Am J Physiol 275 6 Pt. 1 1998 C1630 C1639
55. P. Robin, B. Rossignol, and M.N. Raymond Effect of microtubule network disturbance by nocodazole and docetaxel (Taxotere) on protein secretion in rat extraorbital lacrimal and parotid glands Eur J Cell Biol 67 3 1995 227 237
56. S. Van De Moortele, R. Picart, A. Tixier-Vidal, and C. Tougard Nocodazole and taxol affect subcellular compartments but not secretory activity of GH3B6 prolactin cells Eur J Cell Biol 60 2 1993 217 227
57. T.H. Lee, S. Seng, and M. Sekine Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1 PLoS Med 4 6 2007 e186
58. N. Denduluri, S.X. Yang, and A.W. Berman Circulating biomarkers of bevacizumab activity in patients with breast cancer Cancer Biol Ther 7 1 2007 1
59. S. Lee, T.T. Chen, and C.L. Barber Autocrine VEGF signaling is required for vascular homeostasis Cell 130 4 2007 691 703
60. M. Weigand, P. Hantel, R. Kreienberg, and J. Waltenberger Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro Angiogenesis 8 3 2005 197 204
61. M.W. Jackson, J.S. Roberts, and S.E. Heckford A potential autocrine role for vascular endothelial growth factor in prostate cancer Cancer Res 62 3 2002 854 859
62. J. Zhu, E.C. Beattie, and Y. Yang Centrosome impairments and consequent cytokinesis defects are possible mechanisms of taxane drugs Anticancer Res 25 3B 2005 1919 1925
63. H. Hernandez-Vargas, J. Palacios, and G. Moreno-Bueno Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis Oncogene 26 20 2007 2902 2913